Integra LifeSciences recently announced the acquisition of biologics and foot and ankle product offerings from Metasurg.
The transactions, which closed in December, will allow Integra distribution rights to the entire line of foot and ankle implant solutions from Metasurg. Integra will also be able to distribute Metasurg’s amniotic product line of Biofix Regenerative Biologics, a biologic allograft derived from human placental tissue. This will add to the product line wound care offerings for the company.
Integra expects minimal long-term financial impact as a result of the acquisition, with slower growth during the transition period prior to a return to double-digit growth over the long term, according to a company release.